{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.69","upperLimit":"20.57","value":"14.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of first dose of study treatment to the date of the first documented disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)"}],"paramType":"MEDIAN","populationDescription":"Safety Population was defined as all participants who received at least 1 dose of any study drug. Participants without documentation of PD or death were censored at the date of last response assessment that was SD or better prior to the date of the alternative therapy.","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Progression Free Survival (PFS) in RRMM Participants","type":"SECONDARY","unitOfMeasure":"months"}